Arax Advisory Partners’s Nektar Therapeutics NKTR Stock Holding History

Arax Advisory Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$628	Buy	+9	New	+$659	﹤0.01%	4992
2026 Q1	–	Sell	-2	Closed	-$85	–	4160
2025 Q4	$85	Sell	2 -7	-78%	-$392	﹤0.01%	3855
2025 Q3	$512	Buy	+9	New	+$298	﹤0.01%	3369
2022 Q4	–	Sell	-18	Closed	-$1K	–	1323
2022 Q3	$1K	Hold	18	–	–	﹤0.01%	1120
2022 Q2	$1K	Buy	+18	New	+$1.14K	﹤0.01%	1084

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's NKTR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 9 shares worth $628. The stake represents ﹤0.01% of the portfolio and ranks #4992 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in NKTR as recently as Q4 2025.

Arax Advisory Partners first reported a position in NKTR in Q2 2022 and has held it in 5 quarters since. The position peaked at $1K in Q3 2022. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Arax Advisory Partners held 9 shares of Nektar Therapeutics worth $628 as of Q2 2026.
Nektar Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Nektar Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4992 holding.
Arax Advisory Partners first reported a position in Nektar Therapeutics in Q2 2022 and has held it in 5 quarters since.
Arax Advisory Partners's Nektar Therapeutics position peaked at $1K in Q3 2022.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.